Drug Delivery Technology
Total Trials
4
As Lead Sponsor
2
As Collaborator
Total Enrollment
64
NCT03481842
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 10, 2021
Completion: Oct 10, 2021
NCT05366829
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Phase: Phase 2
Role: Collaborator
Start: Jul 25, 2022
Completion: Jun 1, 2027
NCT03426254
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Phase: Phase 1
Start: Nov 10, 2022
Completion: Jan 10, 2024
NCT07077616
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
Phase: Early Phase 1
Start: Jul 1, 2025
Completion: Dec 1, 2029
Loading map...